Psoriasis or "Psoriases"?

Giornale Italiano di Dermatologia e Venereologia

Volumn 148, Issue 6, 2013, Pages 649-650

  Balato, A ^a   Di Costanzo, L ^a   Patruno, C ^a   Ayala, F ^a   Megna, M ^a   Balato, N ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA C ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; INTERLEUKIN 33; MESSENGER RNA; PROTEIN P40; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

COMORBIDITY; DISEASE COURSE; EDITORIAL; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; INCIDENCE; ONSET AGE; PREVALENCE; PSORIASIS; REGULATORY T LYMPHOCYTE;

AGE OF ONSET; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; PREVALENCE; PROTEINS; PSORIASIS; RISK FACTORS; TERMINOLOGY AS TOPIC; WORLD HEALTH;

EID: 84895808357     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (15)

1. Ferrándiz C, Pujol RM, García-Patos V, Bordas X, Smandía JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002;46:867-73.
2. Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype? Int J Dermatol 2012;51:53-8.
3. Yan KX, Fang X, Han L, Zhang ZH, Kang KF, Zheng ZZ et al. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris. Br J Dermatol 2010;163:48-56.
4. Balato A, Lembo S, Mattii M, Schiattarella M, Marino R, De Paulis A et al. IL-33 is secreted by psoriatic keratinocytes and induces proinflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 2012;21:892-4.
5. Towne JE, Sims JE. IL-36 in psoriasis. Curr Opin Pharmacol 2012;12:486-90.
6. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011;18:620-8.
7. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010;34:314-21.
8. Namazi MR. Why is psoriasis uncommon in Africans? The influence of dietary factors on the expression of psoriasis. Int J Dermatol 2004;43:391-2. (Pubitemid 38714608)
9. Balato N, Di Costanzo L, Patruno C, Patrì A, Ayala F. Effect of weather and environmental factors on the clinical course of psoriasis. Occup Environ Med 2013;70:600.
10. Wu D, Wu Y, Liu JL, Wang B, Zhang XD. Association between HLA-Cw*0602 polymorphism and psoriasis risk: a meta-analysis. Genet Mol Res 2011;10:3109-20.
11. Wohlrab J, Fiedler G, Gerdes S, Nast A, Philipp S, Radtke MA, et al. Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 2013;305:91-8.
12. Prieto-Pérez R, Cabaleiro T, Daudén E, Abad-Santos F. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J 2013;Jan 22.
13. Waisman A. To be 17 again - anti-interleukin-17 treatment for psoriasis. N Engl J Med 2012;366:1251-2.
14. Splus PI, Hooft L. Brodalumumab and ixekizumab, anti-interleukin-17 receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol 2012;167:710-5.
15. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011;365:1586-96.